Our RESETTM clinical trials with rese-cel (investigational CD19-CAR T cell therapy) in lupus, myositis, systemic sclerosis, myasthenia gravis, and pemphigus vulgaris are now recruiting.
| Date | Form | Description | XBRL | Pages | |
|---|---|---|---|---|---|
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 03/02/26 | 4 | Statement of changes in beneficial ownership of securities |
|
1 | |
| 02/18/26 | SCHEDULE 13G | Statement of Beneficial Ownership by Certain Investors |
|
7 | |
| 02/17/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 02/17/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
5 | |
| 02/17/26 | SCHEDULE 13G/A | Statement of Beneficial Ownership by Certain Investors |
|
4 |
